Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda (Pembrolizumab) as a Single Agent Compared to Doublet Chemotherapy for NSCLC
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Case Based Panel Discussion - Advanced Non Squamous NSCLC, Low PD-L1 No Driver Mutation - Is There a Best Systemic Therapy Option?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Case Based Panel Discussion - What is the Optimal Approach for a Fit Patient with Advanced Squamous NSCLC and Low Tumor PD-L1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
- 1 of 46
- View More
The Global Resource for Advancing Cancer Education (GRACE) in partnership with Swedish Cancer Institute presents: Local Therapies for...
Download slides from LIVE WEBCAST of November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
Many physicians worship evidence-based medicine, which is generally a very good practice that ensures that medical practice isn’t dictated by our...
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
- 1 of 201
- View More
Greetings all, I'm a medical doctor from Vietnam. I want to discuss to you about my patient. He is 58 years old, he is hospitalize with chronic...
Hi Grace Members, Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who,...
Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Hello friends, My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative) was diagnosed in 2014, underwent VATS and pleurodesis,...
This question is not for a specific patient, it is designed to understand how oncologists would approach this problem. There’s a 50 year old stage...
- 1 of 6
- View More